The case for buying biotech stocks has strengthened following the election of Donald Trump to the White House. More
Biotech StocksBiotechnology has been one of the fastest advancing industries in the past decade. With new medicine always being synthesized and new ways to fertilize crops, the sector is diverse and prosperous, especially as corporations look for new findings or better efficiency. Subsequently, the biotech stocks are booming and should continue to rise in the future.
Some of the best biotech stocks to buy in 2014 include Amgen (NYSE:AMGN) and Gilead Sciences (NYSE:GILD) although many smaller biotech corporations are on the rise and worth a consideration. Biotech stocks can cure your ailing portfolio and lead you down the road to recovery.
Biotechnology Sector Quote (CIX: MSECTOR5151)
The volatility of biotech shares makes biotech investing among the most lucrative ways to invest. Here's a great way to start... More
Biotech and pharmaceutical companies headed lower and not because of the election. Here's why you should sell these stocks More
The iShares Nasdaq Biotechnology ETF (IBB) has dwindled over the past few weeks. Now, it's on a hair-thin line of support that bulls and bears alike should watch. More
CELG stock now sits at a critical technical juncture with two paths to take after Celgene experienced a wild ride in late July and August. More
The iShares Nasdaq Biotechnology ETF (IBB) has settled into a constructive-looking phase. The path of least resistance? North! More
While the intermediate-term trend remains intact for the IBB etf, earnings season for large biotech companies could be make-or-break. More
Active investors and traders should look to play the iShares Nasdaq Biotechnology Index (ETF) (IBB) to the short side until the picture changes. More
Stemcentrx's acquisition does little to alleviate the risk of the potential decrease in sales once Humira loses patent protection. More